Posted on

Unmasking the Silent Enemy: CDC Urges Universal Hepatitis B Screening for All Adults

liver cirrhosis - hepatitis b symptom

In the depths of our existence, there exists a silent danger, lurking within the veins of countless souls. It is the hepatitis B virus, a sly adversary that often remains undetected, wreaking havoc on our bodies and stealing away our precious vitality. The time has come for us to confront this hidden enemy, to embark on a journey of self-discovery and empowerment.

In a realm governed by the CDC, a clarion call resounds through the corridors of healthcare. It suggets that every adult, without exception, should undergo testing for the hepatitis B virus at least once in their lifetime. But this is not a mere recommendation; it is a profound shift in approach, a departure from the limitations of a risk-based perspective. The aim is to tear down the wall of ignorance, to shine a relentless light upon the prevalence of infection, and to safeguard against the perils of chronic disease and premature demise.

As I immerse myself in the pages of the Morbidity and Mortality Weekly Report, penned by the insightful Erin E. Conners and her esteemed colleagues, I am captivated by their words. They speak of a holistic screening process, a triple-panel test that delves deep into the secrets of the virus. Hepatitis B Virus surface antigen (HBsAg), antibodies to them (anti-HBs), and total hepatitis B core antibody (anti-HBc) are the keys that unlock the hidden truths within our bloodstream.

This grand endeavor is not merely an isolated act; it dances in harmony with the 2022 Advisory Committee on Immunization Practices (ACIP) recommendation. Like intertwined threads in the tapestry of health, screening and vaccination intertwine to form a formidable defense. For through screening, we uncover the echoes of past encounters with the virus, while vaccination shields us from future threats and the need for further testing.

In the vast expanse of the United States, a staggering number loom in the shadows, their knowledge of infection shrouded in darkness. The CDC’s report reveals a disheartening truth: an estimated two-thirds of those living with the Hepatitis B are unaware of their condition. It is a silent epidemic, silently draining vitality and inflicting substantial morbidity and mortality upon 1.89 million souls trapped in the clutches of chronic infection. A haunting fact emerges—those born abroad bear the weight of this burden, accounting for three-fourths of the cases within our borders.

The consequences of this hidden foe are dire, casting a long shadow over our well-being. Those afflicted with chronic Hepatitis B are cast into the abyss of heightened risk, where liver cancer and cirrhosis lurk, ready to claim their toll. Premature death becomes a haunting specter, stalking its victims with a 70-85% greater likelihood than the general population.

Yet, amidst these dark clouds, a glimmer of hope emerges. Though a cure remains elusive, the report offers solace in the form of antiviral treatment, monitoring, and liver cancer surveillance. By embracing these interventions, we can diminish the suffering inflicted by this relentless adversary.

Once upon a time, the realm of screening recommendations was a labyrinth of complexity, reserved for specific groups deemed at risk. Pregnant women, infants born to infected mothers, household contacts, partners, and those exposed to the virus through various means were the chosen few. But as the winds of change swept across the land, the guidelines underwent transformation. In 2008, a new era dawned, expanding the scope of screening to include those born in regions with high Hepatitis B prevalence, individuals engaged in behaviors that exposed them to the virus, recipients of certain therapies, and those with unexplained liver disease.

Now, a new chapter unfolds before us. The CDC’s recommendations cast aside the shackles of disclosure, offering testing to anyone who seeks it. The stigma that once silenced voices is confronted head-on, allowing all to step into the light of knowledge.

In the sacred realm of pregnancy, a special resonance echoes. The report calls for testing in the first trimester, an essential step in safeguarding both the mother and the precious life she carries. Vaccination status and testing history become insignificant in the face of this mandate. And yet, should a pregnant soul have been recently screened and remained unexposed to Hepatitis B risks, only HBsAg screening is advised, a gentle touch in the delicate dance of protection.

But the tapestry is not complete without the thread of continual vigilance. Those at higher risk, regardless of age, are urged to undergo periodic testing as long as the specter of risk persists. The definition of high-risk individuals expands, encompassing the incarcerated and formerly incarcerated, those with a history of sexually transmitted infections or multiple partners, and even those who have encountered the hepatitis C virus. No stone is left unturned in this quest for awareness.

As I ponder the words of the CDC, I am struck by a disheartening truth. The rate of acute Hepatitis B virus infection lingers, an unwelcome presence in our population. In 2019, it plagued 1.0 per 100,000 of our population, its relentless grip refusing to loosen. However, a glimmer of hope shines through the darkness. Routine vaccination has kept the rate at a mere 0.1 cases or below for those up to 19 years of age, a testament to the power of preventive measures.

Yet, even in the realm of adults, the embrace of vaccination remains suboptimal. A ray of light pierces the haze as the 2023 adult immunization schedule now proudly bears the recommendation for Hepatitis B vaccination. A new dawn beckons, calling upon us to seize the opportunity to protect ourselves.

As an adult embarks on the journey of Hepatitis B testing, a sacred ritual unfolds. Blood is drawn, a tangible symbol of our commitment to self-discovery and protection. For those who have not completed the vaccine series, a beacon of hope emerges. The report urges healthcare providers to offer vaccination at the same visit or an associated provider visit, ensuring a seamless path towards fortification. But heed this cautionary note: blood collection must precede vaccination, for the specter of transient HBsAg positivity lingers for up to 18 days after the vaccine’s embrace.

Through the guidance of the CDC, we can transcend the limitations of risk-based approaches, embracing a universal perspective that leads to heightened awareness and reduced suffering. Let us heed the call to action, for within our hands lies the power to protect ourselves and those around us.